Cognition Therapeutics (CGTX) Common Equity (2020 - 2026)
Cognition Therapeutics (CGTX) posted quarterly Common Equity of $29.9 million for Q1 2026, up 143.77% year-over-year from $12.3 million in Q1 2025, and down 12.72% quarter-over-quarter from $34.3 million in Q4 2025.
Cognition Therapeutics (CGTX) Common Equity (2020 - 2026) Analysis & Trends
Cognition Therapeutics (CGTX) has reported Common Equity for 7 consecutive years, with $29.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 143.77% year-over-year to $29.9 million; the TTM figure through Mar 2026 stood at $29.9 million (up 143.77% YoY), while the FY2025 annual figure was $34.3 million, up 82.78% from the prior year.
- Common Equity fell to $29.9 million in Q1 2026 per CGTX's latest filing, from $34.3 million in the prior quarter.
- Across five years, Common Equity topped out at $48.7 million in Q1 2022 and bottomed at $7.0 million in Q2 2025.
- Historically, Common Equity has averaged $29.5 million across 5 years, with a median of $29.9 million in 2026.
- Annual changes were most pronounced in 2022 — Common Equity soared 171.83% — and 2025, when it sank 69.45%.
- Cognition Therapeutics' Common Equity stood at $40.2 million in 2022, then slumped by 39.19% to $24.5 million in 2023, then decreased by 23.39% to $18.8 million in 2024, then surged by 82.78% to $34.3 million in 2025, then fell by 12.72% to $29.9 million in 2026.
- Business Quant data shows CGTX's Common Equity at $29.9 million in Q1 2026, $34.3 million in Q4 2025, and $36.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.79 Bn |
| 10 | Cognition Therapeutics | 90.18 Mn | 90.18 Mn | - | 33.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 33.02 Mn |
| Mar 31, 2026 | 29.91 Mn |
| Dec 31, 2025 | 34.27 Mn |
| Sep 30, 2025 | 36.53 Mn |
| Jun 30, 2025 | 7.03 Mn |
| Mar 31, 2025 | 12.27 Mn |
| Dec 31, 2024 | 18.75 Mn |
| Sep 30, 2024 | 14.48 Mn |
| Jun 30, 2024 | 23.01 Mn |
| Mar 31, 2024 | 28.86 Mn |
| Dec 31, 2023 | 24.47 Mn |
| Sep 30, 2023 | 28.93 Mn |
| Jun 30, 2023 | 34.39 Mn |
| Mar 31, 2023 | 35.78 Mn |
| Dec 31, 2022 | 40.25 Mn |
| Sep 30, 2022 | 39.32 Mn |
| Jun 30, 2022 | 43.90 Mn |
| Mar 31, 2022 | 48.74 Mn |
| Dec 31, 2021 | 51.27 Mn |
| Sep 30, 2021 | -86.72 Mn |